<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01768156</url>
  </required_header>
  <id_info>
    <org_study_id>Meta-Four</org_study_id>
    <secondary_id>2010-A00152-37</secondary_id>
    <nct_id>NCT01768156</nct_id>
  </id_info>
  <brief_title>Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer</brief_title>
  <acronym>Meta-Four</acronym>
  <official_title>Determination of the Prognostic and Predictive Value of the New Marker HE4 in Metastatic Ovarian Cancer Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HE4 is a new marker that could improve the detection of ovarian cancer. The HE4 assay may&#xD;
      have an advantage over the CA-125 assay in that it is less frequently positive in patients&#xD;
      with non malignant disease. Since the evaluation of HE4 for detection and diagnosis of&#xD;
      ovarian cancer is well known, the behaviour of the marker during chemotherapy and follow-up&#xD;
      period after treatment in metastatic ovarian cancer should be studied. It could be used in&#xD;
      patient with non CA-125 secretary tumors. Prognosis and predictive value of HE4 should be&#xD;
      compared with information provided by CA-125. The kinetics of HE4 values after treatment&#xD;
      should be also analysed to determine the role that HE4 could play in the detection of&#xD;
      recurrences during the follow-up of metastatic patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2010</start_date>
  <completion_date type="Actual">November 15, 2016</completion_date>
  <primary_completion_date type="Actual">September 22, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the predictive and prognostic value of HE4 marker</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the rate of patients without elevation of CA-125 presenting an elevation of HE4 that could be used for monitoring the disease.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Metastatic Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental arm</intervention_name>
    <description>Serum samples are collected:&#xD;
at time of diagnosis of recurrence (before 1st chemotherapy)&#xD;
during each cycle of chemotherapy&#xD;
after the end of chemotherapy&#xD;
every 3 month until treatment failure (3-6 samples)&#xD;
stop at the progression or after 18 months post chemotherapy</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proved epithelial ovarian cancer (serous, mucinous, clear cell,&#xD;
             endometrioid, undifferentiated type)&#xD;
&#xD;
          -  Recurrence of anytime necessitating a new line of chemotherapy&#xD;
&#xD;
          -  Patient having received adjuvant chemotherapy&#xD;
&#xD;
          -  Informed consent signed prior any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 3 lines of chemotherapy&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  History of other cancers within the past 5 years (except curatively treated&#xD;
             non-melanoma skin cancer and in situ cervical cancer)&#xD;
&#xD;
          -  Psychological, social, geographical disorders or any other condition that would&#xD;
             preclude study compliance (treatment modalities and study follow-up).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Bergoni√©</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle-Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 9, 2013</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>biomarker</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

